Dong-A ST Co. Ltd. has reported new eukaryotic translation initiation factor 2α kinase 4 (GCN2) inhibitors as potentially useful for the treatment of cancer, infections, neurodegenerative and metabolic diseases.
Research at Dana-Farber Cancer Institute Inc. has led to the identification of new interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Increasing knowledge on chronic lymphocytic leukemia (CLL) proliferation processes suggests that targeting not only leukemic cells but also the tumor microenvironment (TME) and their interactions across drug combination strategies may lead to advances in this complex setting.
Researchers from Sun Yat-Sen University and MD Anderson Cancer Center have compared the proteins secreted by hepatocellular carcinoma (HCC) cells in responders and nonresponders to the anti-PD-1 antibody nivolumab.
Theryq SAS and Gustave Roussy, a European center for cancer research, were given €38 million (US$40.1 million) in funding by Bpifrance, the French public sector investment bank, to further develop Flashdeep, a flash radiotherapy device that uses extremely high energy electron (VHEE) radiation to treat cancers that are resistant to traditional treatments.
Acute myeloid leukemia (AML) presents high recurrence and low survival rates due to drug resistance and different gene mutations that contribute to the difficulty of being cured. Cyclin-dependent kinase 8 (CDK8) is a key oncogenic driver in AML and thus considered a therapeutic target worth exploring.
Researchers from China Medical University (Taiwan) and affiliated organizations have published results from a study that aimed to identify generic variants within the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway that could represent novel biomarkers in patients with prostate cancer.
RSS
